RrhoidCath™by New MedTek Devices

An Australian medical device company focused on transforming recovery from painful surgeries.

New MedTek Devices Pty Ltd is a Sydney-based medical-device company that has developed RrhoidCath™, a breakthrough catheter-based system for post-haemorrhoidectomy pain management. The RrhoidCath™ is designed to improve pain relief and reduce opioid consumption.

Proudly Australian

Designed and made
in Australia.

RrhoidCath™ is designed and manufactured in Sydney, developed in conjunction with an Australian colorectal surgical team.

  • Designed in Sydney, NSW
  • Manufactured in Australia
  • Developed and tested with an Australian hospital and surgical team

Our Team.

Full profiles

Executive team

  • Greg Plamondon, Chief Executive Officer of New MedTek Devices
    Previously: Saluda Medical · Cochlear (AU + US)
    Greg Plamondon
    Chief Executive Officer

    Senior medical device executive with 25+ years across early-stage ventures and established global organisations, focused on advancing patient care through innovation and commercial execution.

  • Val Theisz, Head of Quality and Regulatory at New MedTek Devices
    Val Theisz
    Head of Quality & Regulatory

    Regulatory affairs professional with 15+ years in medical devices, including active implantables, spanning the full product lifecycle across major markets.

  • James Bencke, Head of Product and Operations at New MedTek Devices
    James Bencke
    Head of Product & Operations

    Medtech product and operations leader with 15+ years taking ideas and research through to market, with deep tech, automation, data, and AI expertise.

Board of Directors

  • Gary Zamel, Chairman of New MedTek Devices
    Gary Zamel
    Chairman

    Serial entrepreneur with 35 years establishing, scaling, and exiting technology and product-led Australian companies; founder and Chairman of New MedTek Devices, and Chairman of IBD Medical and Quantum Lock.

  • Professor David Lubowski AM FRACS, Non-Executive Director
    Professor David Lubowski
    Non-Executive Director

    Colorectal surgeon with 30 years of operative experience, Head of Colorectal Surgery and of the Division of Surgery at St George Hospital, Sydney, and a prolific peer-reviewed author.

  • Leslie Butterfield, Non-Executive Director
    Leslie Butterfield
    Non-Executive Director

    Former listed-multinational CEO with 25+ years as a Non-Executive Director and adviser, and wide-ranging commercialisation expertise across manufacturing, medical, and IT.

  • Dr Bronwyn Evans, Non-Executive Director
    Boards: EBR Systems · Building 4.0 CRC · ACOR Consultants
    Dr Bronwyn Evans
    Non-Executive Director

    Healthcare executive with senior leadership across industry and government; formerly CEO of Engineers Australia, CEO of Standards Australia, and SVP Clinical & Regulatory at Cochlear.

Advisory committee

  • Professor Graham Newstead AM, Colorectal Surgery advisor
    AM · Advisor, ASCRS International Committee
    Professor Graham Newstead
    Colorectal Surgery

    Colorectal surgeon of 45+ years with specialty depth in proctology; Medical Director of Bowel Cancer Australia and Chairman of the International Council of Coloproctology.

  • Dr Steven D Wexner, Colorectal Surgery advisor
    1,200+ peer-reviewed manuscripts
    Dr Steven D Wexner
    Colorectal Surgery

    Colorectal surgeon with 38+ years of clinical, academic, and research experience; System Chief of Colorectal Surgery for MedStar Health, Professor of Surgery at Georgetown, and Editor-in-Chief of Surgery.

  • Professor Peter Farrell, Medtech & Entrepreneurship advisor
    Professor Peter Farrell
    Medtech & Entrepreneurship

    Medical device executive and entrepreneur, Founder and Chair of ResMed Inc, member of the US National Academy of Engineering, and Chair of Arcturus Therapeutics.

  • Dr Joshua Gunn, Diagnostics & Reimbursement advisor
    Dr Joshua Gunn
    Diagnostics & Reimbursement

    Chief scientist with 15+ years in diagnostics, specialising in the development and commercialisation of novel technologies and the coding, coverage, and reimbursement that bring them to market.

Want to know more about New MedTek Devices or RrhoidCath™?